8 To 10 Amino Acid Residues In Defined Sequence Patents (Class 530/328)
  • Patent number: 11878053
    Abstract: The invention relates to prophylaxis and therapy of cancer. In particular there is provided a protein Tryptophan 2,3-dioxygenase (TDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of TDO or peptides derived thereof or TDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to TDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: January 23, 2024
    Assignee: IO Biotech ApS
    Inventor: Mads Hald Andersen
  • Patent number: 11578106
    Abstract: Provided are a surfactant adhesive protein comprising an amphiphilic peptide, as a surfactant adhesive protein, at the carbon or amine terminal, a silicone oil and an anticancer composition comprising the surfactant adhesive, where the surfactant adhesive enables homogeneous dispersion of hydrophilic or hydrophobic particles in a hydrophobic or hydrophilic solvent on the basis of strong adhesive strength of the mussel adhesive protein, and the surface adhesive can be favorably used as a surface coating agent requiring antibacterial or antiviral functions as well as a cosmetic product or an ink.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: February 14, 2023
    Assignee: TME THERAPEUTICS CO., LTD.
    Inventors: Sang Jae Lee, Bong Jin Hong, Min Chul Park
  • Patent number: 11492378
    Abstract: The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (Accession number: KCTC 12854BP), which has the ability to kill Enterococcus faecium and an amino acid sequence represented by SEQ ID NO: 2, a pharmaceutical composition containing the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium using the pharmaceutical composition.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: November 8, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Myung Soo Kang, Soo Youn Jun, Jong Hyun Kim, Gi Mo Jung, Jee Soo Son, Hyoun Rok Paik, Sang Hyeon Kang
  • Patent number: 11472838
    Abstract: The invention relates to a compound of general formula (I) as novel inhibitor of blood coagulation factor XIII, methods for synthesis thereof and to use thereof for the prophylaxis or treatment of diseases associated with blood coagulation factor XIII.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: October 18, 2022
    Assignee: Zedira GmbH
    Inventors: Martin Hils, Ralf Pasternack, Christian Büchold
  • Patent number: 11419925
    Abstract: Disclosed herein are compositions and methods for treating cancer and in particular vaccines that treat and provide protection against tumor growth.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 23, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Jian Yan, Karuppiah Muthumani, Jewell Walters
  • Patent number: 11371999
    Abstract: The description relates to a method and kits for determining the total carbonylation level on a polypeptide.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: June 28, 2022
    Assignees: University of Kansas, Genentech, Inc.
    Inventors: Anna Mah, Christian Schoeneich, Yi Yang, Di Gao, Lynn A. Gennaro
  • Patent number: 11230579
    Abstract: The present invention provides an antagonist of a Bcl-2 prosurvival protein containing a BH3-like domain. The antagonist of the invention comprises ARTS and any fragment or peptide that comprises a BH3-like domain. The invention further provides compositions, combined compositions and kits as well as methods for treating Bcl-2 over-expressing disorders.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: January 25, 2022
    Assignee: CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD.
    Inventor: Sarit Larisch
  • Patent number: 11149063
    Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: October 19, 2021
    Assignee: ALBA THERAPEUTICS CORPORATION
    Inventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
  • Patent number: 11124581
    Abstract: The present invention relates to a method for producing a population of nucleic acids encoding at least one protein comprising at least one immunoglobulin variable domain having a non-human-derived CDR3 amino acid sequence embedded in essentially human framework sequences, as well as to a population of nucleic acids and a population of proteins relates thereto and uses thereof.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: September 21, 2021
    Assignee: CHARLES RIVER LABORATORIES, INC.
    Inventor: Jacob Glanville
  • Patent number: 11117946
    Abstract: The present invention refers to a method for preparing a glucagon-like peptide, comprising precipitation of the peptide or of a precursor peptide by means of mixing with an anti-solvent comprising diisopropyl ether and acetonitrile. Further, the present invention also relates to a peptide conjugated to a solid phase and a pharmaceutical composition comprising a Liraglutide peptide obtainable from a method according to the present invention.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: September 14, 2021
    Inventors: Guenther Loidl, Benjamin Neuhaus, Ralph O. Schoenleber, Andreas Stadelmaier
  • Patent number: 11104705
    Abstract: Methods for removing bacterial toxins such as lipopolysaccharide and lipoteichoic acid from a biological fluid with a peptide selected from KKIRVRLSA (SEQ ID NO:1), RRIRVRLSA (SEQ ID NO:2), KRIRVRLSA (SEQ ID NO:3) and RKIRVRLSA (SEQ ID NO:4), the peptide being covalently attached to a solid support through the C-terminus, optionally with the interposition of a linker.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: August 31, 2021
    Assignee: SETLANCE S.R.L.
    Inventors: Alessandro Pini, Chiara Falciani, Luisa Bracci, Jlenia Brunetti, Leila Quercini
  • Patent number: 11013780
    Abstract: Further according to the present disclosure, there are methods for promoting egg maturation in assisted reproductive technologies, such as in in vitro fertilization (IVF) or in an embryo transfer (ET) process. There are also methods for decreasing the rate of ovarian hyperstimulation syndrome (OHSS), providing comparable or improved pregnancy rates, decreasing the time to pregnancy, and inhibiting premature ovulation. The methods include the step of administering a therapeutically effective amount of an active pharmaceutical ingredient of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl) hydrazinocarbonyl-L-leucyl-N?-methyl-L-arginyl-L-tryptophanamide or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: May 25, 2021
    Assignee: Myovant Sciences GmbH
    Inventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, Laura Ann Williams
  • Patent number: 11000572
    Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: May 11, 2021
    Assignee: TOKUSHIMA UNIVERSITY
    Inventors: Akihito Yamamoto, Minoru Ueda, Kohki Matsubara, Akio Suzumura, Koichi Furukawa, Yoshihiro Matsushita, Hirotaka Wakayama, Nobunori Takahashi, Shin Tsunekawa, Takako Izumoto
  • Patent number: 10864283
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating a keloid disease or scars. The inventors of the present invention discovered that mortalin expression inhibition and the interaction between mortalin and p53 may be new targets for keloid treatment. In the present invention, apoptosis and an anti-fibrotic effect were verified by preparing a mortalin-specific shRNA (dE1-RGD/GFP/shMOT) and injecting same in a keloid spheroid. Thus, by reducing ECM expression and inducing apoptosis in a keloid spheroid, mortalin knockdown may be very usefully employed for keloid treatment.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: December 15, 2020
    Inventors: Chae Ok Yun, Won Jai Lee
  • Patent number: 10822376
    Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO:1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: November 3, 2020
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Friedrich Scheiflinger, Michael Dockal
  • Patent number: 10723777
    Abstract: The present disclosure relates to peptides exhibiting an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fats as well as an outstanding anti-diabetes effect by effectively lowering blood sugar levels. The peptides that downregulate the expression of the adipogenic markers PPAR?, ACC and/or aP2, upregulate the expression of the lipolytic factors pHSL, AMPK-?1, CGI-58 and/or ATGL, and reduce sizes of adipocyte and levels of cholesterol in blood are described. The excellent activity and stability of the peptides described herein provides advantages in applications such as drugs and quasi-drug products.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: July 28, 2020
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 10711039
    Abstract: Melanocortin receptor-specific peptides with a C-terminal naphthylalanine of the formula: where R4, R7, R9, R11, R18, R20, R21a, R21b, R21c and R22 are as defined in the claims, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: July 14, 2020
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 10526372
    Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: January 7, 2020
    Assignee: ALBA THERAPEUTICS CORPORATION
    Inventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
  • Patent number: 10526371
    Abstract: Provided are hydrogel-forming peptides that comprise at least one dyad of hydrophobic amino acid residues in which one is a ?3- or ?2-homo amino acid residue. The hydrogels derived from these peptides can be loaded with biological materials and can be used in physiological conditions.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: January 7, 2020
    Assignees: Universiteit Gent, Vrije Universiteit Brussel
    Inventors: Richard Hoogenboom, Annemieke Madder, Steven Ballet
  • Patent number: 10451611
    Abstract: The present invention provides compositions exhibiting in vivo activity of fibrin in an in vitro setting, in vitro assays comprising such compositions, methods of producing such compositions, and methods of using such compositions and assays. The compositions of the invention include molecules with the biochemical properties of 1) high affinity binding to fibrin receptors and 2) activation of cell-signaling systems comparable to that observed in vivo by fibrin. The fibrin compositions of the invention are compatible both in biochemical assays and cell-based assays, and thus useful for in vitro assays for screening of test agents that modulate cell activation and/or signaling pathways mediated by fibrin or associated with fibrin activity.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 22, 2019
    Assignee: THE J. DAVID GLADSTONE INSTITUTE
    Inventors: Katerina Akassoglou, Jae Kyu Ryu, Anke Meyer-Franke
  • Patent number: 10322998
    Abstract: Disclosed are isolated, unnatural polypeptides containing cyclically-constrained ?-amino acid residues and cyclically-constrained ?-amino acid residues. The compounds are unnatural and because they contain rotationally constrained residues that are not amenable to enzymatic degradation, the compounds are useful to probe protein-protein and other large molecule interactions.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: June 18, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Samuel H. Gellman, Ahlke Hayen, Margaret A. Schmitt, Felix N. Ngassa
  • Patent number: 10221225
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: March 5, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Oliver Schoor, Andrea Mahr, Toni Weinschenk, Anita Wiebe, Jens Fritsche, Harpreet Singh
  • Patent number: 10125198
    Abstract: The present invention relates to a method for producing a population of nucleic acids encoding at least one protein comprising at least one immunoglobulin variable domain having a non-human-derived CDR3 amino acid sequence embedded in essentially human framework sequences, as well as to a population of nucleic acids and a population of proteins relates thereto and uses thereof.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: November 13, 2018
    Assignee: Distributed Bio, Inc.
    Inventor: Jacob Glanville
  • Patent number: 10059934
    Abstract: In one aspect, the invention relates to a peptide that forms a calcium-dependent hydrogel using a rationally engineered beta roll peptide. In the absence of calcium, the peptide is intrinsically disordered. Upon addition of calcium, the peptide forms a corkscrew-like structure. In one embodiment, one face of the beta roll is mutated to comprise leucine residues. In some embodiments, a leucine zipper forming helical domain to the engineered beta roll forms hydrogels by physical cross-linking in calcium rich environments.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: August 28, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Scott Banta, Mark A. Blenner, Ian Wheeldon, Kevin Dooley
  • Patent number: 9895411
    Abstract: Materials and methods for treating and preventing an infection or disease, and for directly killing microorganisms, using carboxy-terminal C5a analogs, are provided.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: February 20, 2018
    Assignees: SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Sam D. Sanderson, Joy Arlene Phillips, Edward Leroy Morgan, Marilyn Louise Thoman, Tamsin Sheen, Kelly S. Doran, Elizabeth Louise Virts, Tammy Kielian, Mark Hanke
  • Patent number: 9796784
    Abstract: The present invention features methods and compositions for the generation and use of conformation-specific antibodies or fragments thereof.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: October 24, 2017
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Xiao Zhen Zhou
  • Patent number: 9765114
    Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: September 19, 2017
    Assignees: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Toshio Nishihara, Masashi Gotoh
  • Patent number: 9605024
    Abstract: Protease activated receptor 4 (PAR4) agonist peptides are disclosed. These peptides are useful for developing robust PAR4 receptor assays.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 28, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael G. Kornacker, Claudio Mapelli, Douglas J. Riexinger
  • Patent number: 9598464
    Abstract: The invention provides a method of making a peptide or peptide derivative comprising the amino acid sequence comprising imfwydcye or a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 21, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Friedrich Scheiflinger, Michael Dockal
  • Patent number: 9598463
    Abstract: Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: March 21, 2017
    Assignee: BIOMARCK PHARMACEUTICALS, LTD.
    Inventor: Indu Parikh
  • Patent number: 9580471
    Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: February 28, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoquing Zhang, Kunwar Shailubhai, Stephen Comiskey, Rong Feng
  • Patent number: 9550821
    Abstract: A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject wherein a reduction in ghrelin levels and/or a reduction in ghrelin/unacylated ghrelin ratio is beneficial to the subject. Also, use of ghrelin level and/or ghrelin/unacylated ghrelin ratio as biomarkers for determining a subject's likelihood of responding to and/or benefiting from administration of unacylated ghrelin.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: January 24, 2017
    Assignee: Alize Pharma SAS
    Inventors: Aart Jan Van Der Lely, Thierry Abribat
  • Patent number: 9533975
    Abstract: The present invention cationic amphiphilic polyproline helices (CAPHs) compounds having increased hydrophobicity and cellular internalization as antimicrobial agents. Antimicrobial compositions and methods of using the same are also provided.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: January 3, 2017
    Assignee: Purdue Research Foundation
    Inventor: Jean Anne Chmielewski
  • Patent number: 9457078
    Abstract: The present invention relates to a vaccine comprising at least one peptide consisting of amino acid sequence LRANISHKDMQLGR (SEQ ID No. 1) or a peptide fragment thereof (SEQ ID No. 2-13) coupled or fused to a carrier protein comprising at least one T cell epitope, wherein said peptide fragment comprises at least 7 amino acid residues and the amino acid sequence KDMQLGR (SEQ ID No: 7) or KDMQLG (SEQ ID No: 23) under the provision that the peptide fragment does not consist of amino acid sequences HKDMQLGR (SEQ ID No: 16) and HKDMQLG (SEQ ID No: 22).
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: October 4, 2016
    Assignee: AFFIRIS AG
    Inventors: Guenther Staffler, Christine Landlinger, Frank Mattner
  • Patent number: 9447148
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: September 20, 2016
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 9388216
    Abstract: The present invention relates to agents, compositions and methods for use in medicine. In particular, the invention relates to agents related to GnRH peptides.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: July 12, 2016
    Assignee: Medical Research Council
    Inventors: Robert Peter Millar, Stuart Russell Maudsley, Rakel Lopez De Maturana Garmendia
  • Patent number: 9265811
    Abstract: Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: February 23, 2016
    Assignee: ALBA THERAPEUTICS CORPORATION
    Inventors: Blake Paterson, Mark J. Ginski
  • Patent number: 9249189
    Abstract: The invention relates to compounds that are analogs of a cyclic peptide, cyclo[EKTOVNOGN] (SEQ ID NO: 13), AFPep, that has anti-estrotrophic activity. The analogs of the invention include peptides and peptidomimetics that inhibit estrogen receptor-dependent cell proliferation. The compounds of the invention are useful for treating cell proliferative disorders or physiological conditions characterized by undesirable or unwanted estrogen induced cell proliferation, including breast cancer.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: February 2, 2016
    Assignee: ALBANY MEDICAL COLLEGE
    Inventors: Thomas T. Andersen, Herbert I. Jacobson, James A. Bennett, Leroy Joseph, Alberto Bryan
  • Patent number: 9222071
    Abstract: T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: December 29, 2015
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Ann Moriarty, Didier J. Leturcq, Juli Degraw, Michael R. Jackson, Per A. Peterson, Marja Heiskala
  • Patent number: 9162223
    Abstract: This invention is directed to the production of improved chromatographic resins and method of making and using such resins.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: October 20, 2015
    Assignee: North Carolina State University
    Inventors: Ruben G. Carbonell, Stefano Menegatti, Amith D. Naik
  • Patent number: 9090656
    Abstract: The present invention relates to a liquid (or solution)-phase manufacturing process for preparing the decapeptide Degarelix, its protected precursor, and other useful intermediates. The invention further relates to polypeptides useful in the solution-phase manufacturing process and to the purification of Degarelix itself. Degarelix can be obtained by subjecting a Degarelix precursor according to formula (II): (P1)AA1-AA2-AA3-AA4(P4)-AA5-AA6(P6)-AA7-AA8(P8)-AA9-AA10-NH2 (II) or a salt or solvate thereof, to a treatment with a cleaving agent in an organic solvent, wherein P1 is an amino protecting groups; preferably acetyl; P4 is hydrogen or a hydroxy! protecting group, preferably a hydroxyl protecting group; P6 is hydrogen or an amino protecting groups; preferably an amino protecting groups; and P8 is an amino protecting group.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: July 28, 2015
    Assignee: Ferring B.V.
    Inventors: Jon Holbech Rasmussen, Jens Fomsgaard, Stefan Hansen, Palle Hedengran Rasmussen, Wolfgang Oliver Wachs
  • Patent number: 9073977
    Abstract: The present invention provides for novel peptoid oligomers that are capable of self-assembling into two-dimensional sheet structures. The peptoid oligomers can have alternately hydrophilic or polar side-chains and hydrophobic or apolar side-chains. The peptoid oligomers, and the two-dimensional sheet structures, can be applied to biological applications where the peptoid plays a role as a biological scaffold or building block. Also, the two-dimensional sheet structures of the present invention can be used as two-dimensional nanostructures in device applications.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: July 7, 2015
    Assignee: The Regents of the University of California
    Inventors: Ronald N. Zuckermann, Tammy K. Chu, Ki Tae Nam
  • Patent number: 9068019
    Abstract: The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to be coupled to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved resistance against in vivo protease activity, and thus exhibit improved bioavailability and an improved absorption rate.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: June 30, 2015
    Assignee: HANALL BIOPHARMA CO., LTD.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
  • Publication number: 20150148303
    Abstract: The embodiments are directed to peptides, compositions, and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides.
    Type: Application
    Filed: November 26, 2013
    Publication date: May 28, 2015
    Applicant: NYMOX CORPORATION
    Inventors: Paul AVERBACK, Jack Gemmell
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Publication number: 20150147347
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Inventors: Jens FRITSCHE, Toni WEINSCHENK, Steffen WALTER, Peter LEWANDROWSKI, Harpreet SINGH
  • Publication number: 20150147346
    Abstract: The present invention provides methods of diagnosing, treating, and preventing prion and neurodegenerative disorders including vaccines against prion diseases and neurodegenerative disorders.
    Type: Application
    Filed: May 1, 2013
    Publication date: May 28, 2015
    Inventors: Samuel Bogoch, Elenore S. Bogoch, Anne-Elenore Bogoch Borsanyi, Samuel Winston Bogoch
  • Publication number: 20150148285
    Abstract: The present invention provides an antimicrobial peptide, wherein the amino terminal and/or carboxyl terminal of the peptide is linked with at least one artificial bulkyl amino acid to increase the salt resistance and protease resistance of the antimicrobial peptide. The antimicrobial peptide of the invention has a high salt resistance, a high protease resistance, and a low hemolytic activity, simultaneously.
    Type: Application
    Filed: May 8, 2014
    Publication date: May 28, 2015
    Applicant: National Tsing Hua University
    Inventors: Jya-Wei Cheng, Hui-Yuan Yu, His-Tsung Cheng
  • Patent number: 9040663
    Abstract: The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and/or energy balance and body weight related diseases, disorders and/or conditions, including obesity, overweight and diseases, disorders and/or conditions associated with obesity and/or overweight, such as type 2 diabetes and metabolic syndrome.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: May 26, 2015
    Assignee: AstraZeneca AB
    Inventors: John H. Dodd, Yi-Qun Shi, Wei Yang
  • Publication number: 20150141345
    Abstract: This invention provides novel compounds and methods for promoting cell survival and/or plasticity, especially in neuronal cells, by targeting the microtubule End Binding (EB) proteins and other associated proteins (e.g., drebrin). Methods for identifying potential modulators of cell death/plasticity are also described.
    Type: Application
    Filed: March 12, 2013
    Publication date: May 21, 2015
    Inventors: Illana Gozes, Saar Oz, Jacqueline Woang Cheing Tiong